↓ Skip to main content

Natural Compounds as Therapeutic Agents for Amyloidogenic Diseases

Overview of attention for book
Attention for Chapter 3: Biflavonoids as Potential Small Molecule Therapeutics for Alzheimer's Disease.
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news
1 news outlet
twitter
1 X user

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
31 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Biflavonoids as Potential Small Molecule Therapeutics for Alzheimer's Disease.
Chapter number 3
Book title
Natural Compounds as Therapeutic Agents for Amyloidogenic Diseases
Published in
Advances in experimental medicine and biology, January 2015
DOI 10.1007/978-3-319-18365-7_3
Pubmed ID
Book ISBNs
978-3-31-918364-0, 978-3-31-918365-7
Authors

Thapa, Arjun, Chi, Eva Y, Arjun Thapa, Eva Y. Chi Ph.D., Eva Y. Chi

Editors

Neville Vassallo

Abstract

Flavonoids are naturally occurring phytochemicals found in a variety of fruits and vegetables and offer color, flavor, aroma, nutritional and health benefits. Flavonoids have been found to play a neuroprotective role by inhibiting and/or modifying the self-assembly of the amyloid-β (Aβ) peptide into oligomers and fibrils, which are linked to the pathogenesis of Alzheimer's disease. The neuroprotective efficacy of flavonoids has been found to strongly depend on their structure and functional groups. Flavonoids may exist in monomeric, as well as di-, tri-, tetra- or polymeric form through C-C or C-O-C linkages. It has been shown that flavonoids containing two or more units, e.g., biflavonoids, exert greater biological activity than their respective monoflavonoids. For instance, biflavonoids have the ability to distinctly alter Aβ aggregation and more effectively reduce the toxicity of Aβ oligomers compared to the monoflavonoid moieties. Although the molecular mechanisms remain to be elucidated, flavonoids have been shown to alter the Aβ aggregation pathway to yield non-toxic, unstructured Aβ aggregates, as well as directly exerting a neuroprotective effect to cells. In this chapter, we review biflavonoid-mediated Aβ aggregation and toxicity, and highlight the beneficial roles biflavonoids can potentially play in the prevention and treatment of Alzheimer's disease.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 31 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 4 13%
Student > Bachelor 3 10%
Student > Ph. D. Student 3 10%
Researcher 3 10%
Student > Postgraduate 2 6%
Other 4 13%
Unknown 12 39%
Readers by discipline Count As %
Neuroscience 4 13%
Biochemistry, Genetics and Molecular Biology 3 10%
Pharmacology, Toxicology and Pharmaceutical Science 2 6%
Chemistry 2 6%
Agricultural and Biological Sciences 2 6%
Other 4 13%
Unknown 14 45%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 June 2015.
All research outputs
#3,197,592
of 22,813,792 outputs
Outputs from Advances in experimental medicine and biology
#544
of 4,950 outputs
Outputs of similar age
#47,522
of 353,106 outputs
Outputs of similar age from Advances in experimental medicine and biology
#33
of 272 outputs
Altmetric has tracked 22,813,792 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,950 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,106 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 272 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.